# Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

> **NCT00666926** · PHASE1 · COMPLETED · sponsor: **Verastem, Inc.** · enrollment: 99 (actual)

## Conditions studied

- Head and Neck Neoplasm
- Prostatic Neoplasm
- Pancreatic Neoplasm

## Interventions

- **DRUG:** PF00562271
- **DRUG:** PF00562271
- **DRUG:** PF00562271
- **DRUG:** PF00562271

## Key facts

- **NCT ID:** NCT00666926
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666926, "Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00666926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*